FluoretiQ is a University of Bristol spin-out developing rapid tests that match bacterial infections to targeted treatment from the first visit. FluoretiQ specialises in growth-free, machine-learning powered, point-of-care tests that deliver results in minutes. Its patented technologies, VERI-5® and SCFI™, detect bacterial infections and antibiotic sensitivity directly from samples—reducing the current 3-day process to minutes. FluoretiQ has achieved over 90% accuracy testing with over 600 samples from humans and animals. FluoretiQ has built a team that combines deep technical expertise with a clear commercial, clinical and operational experience. With active collaborations across academia, veterinary and human health, FluoretiQ is uniquely positioned to drive antimicrobial stewardship and tackle the global Antimicrobial Resistance (AMR) crisis.